Photo: Christophe Morin/IP3/Getty Images

Facebook, its investors, and its critics wrestled Wednesday with how to assess the prospect of a $3 billion to $5 billion government fine for the social media giant.

The big picture: On the one hand, that would be a record fine for the FTC, and it's certainly nothing to sneeze at. At the same time, it's likely just a flesh wound to a company that brings in roughly that much revenue every month — and a monetary fine alone provides no guarantee that the company's behavior will change.

Driving the news: In its quarterly earnings filing, the company announced that it has set aside $3 billion to cover its lability before the Federal Trade Commission for a variety of issues, most prominently the Cambridge Analytica privacy scandal.

  • Earlier this year the Washington Post reported the FTC and Facebook were negotiating a “multibillion dollar settlement” to these matters. Facebook’s announcement confirms that reporting and suggests a settlement is near.

Why it matters: A settlement with a fine this size would represent a giant win for an agency that had never imposed a penalty on a tech firm more than around $20 million. But critics say that unless a ruling or deal also includes meaningful changes to Facebook’s practices, it won’t make much difference for a corporation that’s bringing in $55 billion in annual revenue and sitting on a $45 billion cash pile.

Between the lines: The amount is a kind of Goldilocks median for the two parties — big enough for the FTC to claim a record victory, small enough for Facebook to take a brief earnings hit and then keep on minting money.

But, but, but: Investors did not seem rattled, cheering Facebook's revenue and user growth numbers with a 7% gain in after-hours trading.

A few thought bubbles from the Axios tech team:

  • From Axios’ David McCabe: Companies sometimes announce accounting reserves like this for lawsuits, but it’s very rare for a company to publicly preview a federal enforcement penalty. Facebook may have chosen this course to show it's willing to pay a serious price for its infractions.
  • From Sara Fischer: Scandals not withstanding, the company’s advertising business remains healthy. It is big brands that might be most concerned about a reputational risk if Facebook's image tanks, but Facebook's bread and butter is small- and medium-sized advertisers who rely on Facebook as their only efficient option. To that end, Facebook COO Sheryl Sandberg said on Wednesday’s earnings call that Facebook's top 100 advertisers make up less than 20% of revenue.
  • From Ina Fried: Google and Microsoft both absorbed large fines from European authorities with little difficulty. The real impact is when regulators slow a tech company, either through forcing business changes or causing a company to be more cautious with its future bets.

The bottom line: Thanks to Facebook's unusual disclosure (we can't ever remember a company accounting for a regulatory fine that hadn't even been proposed), we know the size of the fine the company could face. But the real question — and potentially the bigger cost to Facebook — is whether regulators impose any new conditions on the company.

Go deeper

Supreme Court Justice Ruth Bader Ginsburg dies at 87

Ruth Bader Ginsburg. Photo: Tom Brenner/Getty Images

Justice Ruth Bader Ginsburg has died of metastatic pancreatic cancer at age 87, the Supreme Court announced Friday evening.

Why it matters: Ginsburg had suffered from serious health issues over the past few years. Her death sets up a fight over filling a Supreme Court seat with less than 50 days until the election.

NYT: White House drug price negotiations broke down over $100 "Trump Cards"

President Trump with Mark Meadows, his chief of staff, on Sept. 3 at Andrews Air Force Base in Maryland. Photo: Mandel Ngan/AFP via Getty Images

Negotiations on a deal between the White House and pharmaceutical industry to lower drug prices broke down last month after Mark Meadows, the president's chief of staff, insisted that drugmakers pay for $100 cash cards to be mailed to seniors before the election, according to the New York Times.

Why it matters: Some of the drug companies feared that in agreeing to the prescription cards — reportedly dubbed "Trump Cards" by some in the pharmaceutical industry — they would boost Trump's political standing weeks ahead of Election Day with voters over 65, a group that is crucial to the president's reelection bid, per the Times.

In photos: Virginians line up for hours on first day of early voting

Photo: Andrew Caballero-Reynolds/AFP via Getty Images

In some parts of Virginia, people waited in line up to four hours to cast their ballots on the first day of early voting, according to the Washington Post.

The big picture: The COVID-19 pandemic seems to already have an impact on how people cast their votes this election season. As many as 80 million Americans are expected to vote early, by mail or in person, Tom Bonier, CEO of TargetSmart, a Democratic political data firm, told Axios in August.